• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    BridgeBio Pharma Stock Gains Focus After Revenue Jump And Pipeline Progress

    Simply Wall St·11/01/2026 11:30:55
    Listen to the news
    • BridgeBio Pharma reported third quarter 2026 revenue of US$353.17 million and a net loss of US$56.71 million, with higher year to date revenue and a smaller nine month loss compared with the prior year period.
    • Management is preparing for three potential U.S. product launches under FDA priority review while continuing to grow ATTR cardiomyopathy therapy Attruby and benefiting from a milestone tied to European partner commercialization.
    • Investors can now consider how BridgeBio Pharma's investment narrative could be influenced by this combination of reported results and pipeline progress.

    Scan beyond BridgeBio Pharma and size up rare-disease momentum across a hand picked set of biopharma players using our 19 high quality undiscovered gems.

    BridgeBio Pharma Investment Narrative Recap

    To own BridgeBio Pharma, you need to believe this is a rare disease platform that can turn today’s concentrated Attruby driven revenue into a broader portfolio over the next few years. The Q3 2026 report, with US$353.17 million in revenue and a net loss of US$56.71 million, keeps that story intact rather than changing it.

    The near term swing factor is clear. FDA outcomes for BBP 418, infigratinib and encaleret could ease reliance on Attruby or leave the business heavily dependent on a single therapy. Higher launch spending and ongoing operating losses remain the biggest operational risk if those approvals do not land as planned.

    The Q3 2026 earnings release is the key operational update to focus on here. Revenue for the quarter reached US$353.17 million, with the nine month figure at US$791.36 million, helped by Attruby and a Bayer milestone. Losses narrowed versus the prior year period, but the company still reported a net loss of US$372.97 million year to date.

    That combination of stronger top line and continuing red ink sets the stage for how investors frame the upcoming PDUFA dates. Execution on BBP 418, infigratinib and encaleret launches now matters not just for growth, but also for easing cash pressure and concentration risk around Attruby if those products secure approval and gain real traction.

    BridgeBio Pharma Long Range Analyst Set Up

    BridgeBio Pharma's narrative projects US$3.0b revenue and US$1.0b earnings by 2029. This assumes 62.1% yearly revenue growth and an earnings swing of roughly US$1.7b from current earnings of a US$691.9m loss to the 2029 consensus profit.

    Uncover how BridgeBio Pharma's fair value indicates a 44% potential upside to its current price before the market closes the valuation gap.

    NasdaqGS:BBIO 1-Year Stock Price Chart
    NasdaqGS:BBIO 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view on BridgeBio Pharma puts the upcoming PDUFA dates at the center of the story. The most optimistic analysts were modeling roughly US$4.6b of revenue and US$1.8b of earnings by 2029. Your read on this fresh Q3 update might shift how credible that rare disease launch curve now looks.

    Explore 5 other BridgeBio Pharma fair value estimates, including one that suggests there could be as much as 291% upside from the current price!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking for more investment ideas beyond BridgeBio Pharma?

    If the BridgeBio Pharma story has sharpened your thinking, broaden your watchlist by using the Simply Wall St Screener to hunt for other stocks that fit your return and risk preferences.